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ABSTRACT 
 
We recently demonstrated that mice lacking epidermal glucocorticoid (GC) receptor (GR) (GR 
epidermal knock-out or GREKO mice) have developmental defects and sensitivity to epidermal 
challenge in adulthood. We examined the susceptibility of GREKO mice to skin chemical 
carcinogenesis. GREKO mice treated with a low dose of DMBA followed by PMA promotion 
exhibited earlier papilloma formation with higher incidence and multiplicity relative to control 
littermates (CO). Augmented proliferation and inflammation, and defective differentiation of 
GREKO keratinocytes contributed to the phenotype, likely through increased AKT and STAT3 
activities. GREKO tumors exhibited signs of early malignization, including delocalized 
expression of laminin A, dermal invasion of keratin (K)5-positive cells, K13 expression, and 
focal loss of E-cadherin. Cultured GREKO keratinocytes were spindle-like, with loss of E-
cadherin and upregulation of smooth muscle actin and Snail, suggesting partial epithelial-
mesenchymal transition. A high DMBA dose followed by PMA promotion generated sebaceous 
adenomas and melanocytic foci in GREKO and CO. Importantly, the number, growth kinetics and 
extent of both tumor types increased in GREKO mice, suggesting that in addition to regulating 
tumorigenesis from epidermal lineages, GR in keratinocytes is important for cross-talk with 
other skin cells. Altogether, our data reinforce the importance of GR in the pathogenesis of skin 
cancer. 
 
INTRODUCTION  
 
Glucocorticoid (GC) derivatives are the most widely used therapeutic agents for treating 
numerous cutaneous diseases (Schmuth et al., 2007). In addition, GCs are routinely used in 
cancer therapy as co-adjuvants to reduce side effects of chemotherapeutic agents and their use 
as immunosuppressors is standardized in the clinical practice (De Bosscher and Haegeman, 
2009; Barnes, 2011). It is thus crucial to understand the mechanisms by which these compounds 
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influence the development and progression of skin tumors in order to improve the design of 
combined therapies to combat cancer. 
Both endogenous and synthetic GCs exert their actions through the ubiquitous 
intracellular GC receptor (GR), a member of the steroid nuclear receptor superfamily of ligand-
dependent transcription factors (De Bosscher and Haegeman, 2009; Revollo and Cidlowski, 
2009; Nicolaides et al., 2010). GR is required for post natal survival and plays a crucial role in 
skin pathophysiology, as demonstrated by the generation and characterization of genetically 
modified mice with gain- and loss-of-function of GR (Cole et al., 1995; Tronche et al., 1998; 
Tuckermann et al., 1999; Pérez, 2011). We previously reported that transgenic mice with 
keratinocyte-specific GR overexpression were highly resistant to developing skin papillomas 
with fewer papillomas that appeared with slower kinetics relative to control mice (Budunova et 
al., 2003). However whether mice lacking GR in the epidermis would be more susceptible to 
tumorigenesis was not known. We recently demonstrated that the selective inactivation of GR in 
mouse epidermis (GR epidermal knock-out or GREKO mice) led to abnormal skin development 
and exacerbated susceptibility to various epidermal challenges in the adult age (Sevilla et al., 
2013). In fact, acute phorbol ester (PMA) treatment of GREKO skin resulted in exaggerated 
epidermal keratinocyte hyperproliferation and increased immune infiltrates. 
With these antecedents, we examined the susceptibility of GREKO mice to skin tumor 
formation and development using two different protocols with distinct doses of initiating and 
promoting agents (Abel et al., 2009). The use of either low or high 12-dimethylbenz(a) 
anthracene (DMBA) dosage followed by distinct dosage of PMA produced either skin 
papillomas or sebaceous tumors and dermal melanocytic foci (MF), respectively, in the mouse 
strain used in this study. GREKO mice exhibited earlier kinetics of skin tumor growth, higher 
tumor incidence and multiplicity as well as increased tumor size, as compared to control 
littermates (CO). Altogether, our data reinforce the importance of GR in the pathogenesis of 
skin cancer. 
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RESULTS AND DISCUSSION 
Augmented sensitivity of GREKO mice to different protocols of DMBA/TPA-induced skin 
carcinogenesis  
We examined the susceptibility of GREKO mice to skin tumor formation and development by 
using different dosage and kinetics of the two-stage DMBA/PMA carcinogenesis protocol. It is 
relevant to highlight that different mouse strains require different concentrations of DMBA and 
PMA for effective tumor formation in this protocol (Abel et al., 2009). In a first set of 
experiments, the dorsal skin of age matched GREKO and CO mice was topically treated with a 
low dose of DMBA (23 nmol) followed by twice weekly doses of PMA (10g). As expected, 
DMBA initiation caused mutation of H-ras in codon 61 (A-T) in papillomas from both 
genotypes (Fig. S1a; Abel et al., 2009). Papillomas developed in GREKO mice at 8 wks after the 
start of promotion and thereafter continued to increase in both number and size (Fig. 1a, b and 
S2). In CO mice, papillomas were not detected until 10 wks and only 75% of animals developed 
tumors relative to 100% of GREKO mice (Fig. S2b). We observed an increase in both the average 
number of tumors per mouse and the total number of tumors developed by GREKO mice relative 
to their CO counterparts, with statistical significance from 10 wks onwards (Fig. 1a and S2b). 
The mean number of papillomas smaller than 2mm was three-fold increased whereas the 
average number of tumors larger than 2 mm was five-fold higher in GREKO relative to CO mice 
(Fig. 1b). We did not observe a statistical bias towards the susceptibility to tumor formation by 
gender within a given genotype (Fig. S2a). 
All CO tumors generated by this protocol were well-differentiated papillomas, the 
epidermal-dermal border was well defined and tumor differentiation was histologically evident 
by the presence of so-called keratin pearls (Fig. 1c-e). GREKO skin tumors were also papillomas 
but they showed several features of poor differentiation including a diffuse epidermal-dermal 
 5
border and frequent signs of keratinocyte atypia (Fig. 1d´, e´; discontinuous lines and arrows). 
Moreover, the expression of laminin A was delocalized in GREKO tumors instead of being 
confined to the basement membrane of the epidermis, as in CO papillomas (Fig. 1f, f´). These 
features were unique to GREKO tumors, since adjacent skin showed similar epidermal 
hyperplasia and basement membrane deposition of laminin as CO (Fig. S3). In 40% of GREKO 
tumors assessed, and none of CO, keratinocytes invaded the underlying dermis, as shown by K5 
immunostaining (Fig. 1g, arrowheads). 
In another set of experiments, a high DMBA dose (390 nmol) followed by three times 
weekly topical application of PMA (6 g) for 31 wks generated sebaceous adenomas as well as 
melanocytic foci (MF) in GREKO and CO littermates (Fig. 2). The generation of sebaceous 
tumors as well as the accumulation of dermal melanocytes, which were visualized as nevi, has 
been reported in other studies using similar high doses of DMBA in different mouse strains 
(Rice and Anderson, 1986; Husain et al., 1991; Indra et al., 2007). In both GREKO and CO mice, 
sebaceous tumors contained the characteristic A-to-T mutation in codon 61 of the H-ras gene 
(Fig. S1a).  
GREKO mice showed early kinetics of sebaceous tumor appearance relative to CO 
littermates (13 wks vs 19 wks) as well as an elevated total tumor number (five-to seven-fold at 
late stages of tumor promotion) (Fig. 2a); however, the histology of GREKO sebaceous tumors 
was indistinguishable to that of controls (Fig. 2b, b´). The sebaceous glands of GREKO mice are 
also targeted by the Krt5 driven recombinase and thus, GR is inactivated in sebocytes (Fig. 
S1b). It has been reported that low levels of -catenin and AP-1 signaling can favor sebaceous 
instead of epidermal tumor formation (Gerdes et al., 2006; Niemann et al., 2007). We observed 
a decrease in levels of -catenin and p-c-Jun in sebaceous tumors relative to the epidermis of 
GREKO and CO mice, however there were no clear differences between genotypes (Fig. S4). 
While we cannot rule out the contribution of other signaling pathways to the development of 
sebaceous adenomas in our experiment, it is likely that the doses and kinetics of DMBA/PMA 
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treatments together with the genetic background are responsible for the generation of sebaceous 
rather than epidermal tumors. 
Regarding the MF, their total number, kinetics of growth and extent was dramatically 
increased in mice lacking epidermal GR (Fig. 2c, d, and d´). We detected a three-fold increase 
of these foci, which appeared on average 3 wks earlier in GREKO relative to CO mice (Fig. 2c). 
In addition, the MF in GREKO mice consistently invaded the deep dermis (Fig. 2, compare d and 
d´). As K5-Cre is not expressed in melanocytes (Fig. S1b), these data highlight a role for 
keratinocytic GR in the regulation of other cell types which populate the skin. Our data are 
consistent with previous results describing that GCs can inhibit melanoma growth in mice, and 
are also compatible with reports indicating that GC-based therapy was protective against 
melanoma incidence in a mediterranean population (Landi et al., 2001).  
Importantly, there were similarities in the response of GREKO mice to chemical 
carcinogenesis protocols and that of mice lacking skin expression of other nuclear hormone 
receptors including retinoid X receptor , peroxisome proliferator-activated receptor and 
vitamin D receptor (Indra et al., 2007). This is likely due to the production of soluble factors 
such as En1, Fgf2 and Scf by keratinocytes, which contributes to melanocyte activation and 
migration (Wang et al., 2011). Analogous to these hormone receptors, the increased skin tumor 
formation and progression of GREKO mice suggests a role for GR as a tumor suppressor in both 
non-melanoma and melanoma skin cancers, as well as in the cross-talk between keratinocytes 
and melanocytes. 
 
Increased keratinocyte proliferation and inflammation in GREKO skin papillomas 
 
Consistent with the growth inhibitory role of GR in keratinocytes, the epidermal-specific loss of 
GR caused an increase of basal keratinocyte proliferation of approximately 30% in transgenic vs 
CO tumors (Fig. 3a, a´ and 3d). In addition, we observed increased suprabasal (white arrows) 
keratinocyte proliferation in GREKO tumors, while the majority of proliferation was confined to 
the basal layer (black arrows) in CO. It is well known that CycD1 is a key target for activated 
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ras in the mouse skin carcinogenesis protocol and that it is an indicator of the proliferative 
response (Robles et al., 1998). We detected augmented CycD1 expression in keratinocytes 
throughout all epidermal layers (Fig. 3b, b´) as well as strong up-regulation of Ccnd1 mRNA 
levels in GREKO tumors (data not shown), which is consistent with the GR-mediated inhibition 
of this gene in mouse epidermis (Surjit et al., 2011). 
GR exerts anti-inflammatory effects in skin and accordingly, the lack of GR in 
keratinocytes resulted in marked immune infiltrates both in the stroma (Fig. 3e´, black arrows) 
and within the epidermal layers of GREKO tumors (Fig. 3e´, white arrows). These histological 
changes correlated with the increased expression of the pro-inflammatory cytokine IL6 in the 
GREKO tumor epithelia relative to CO (Fig. 3f, f´). Since Il6 and other cytokines are 
transcriptional targets of GR repression, we examined the relative mRNA levels of Il6, Tnfa and 
Il1b in the skin of GREKO and CO mice adjacent to the tumors (Fig. 3h). We detected 
statistically significant up-regulation of all cytokines (seven-fold for Il6 and two- to three-fold 
for Tnfa and Il1b) in GREKO skin compared to CO (Fig. 3h), thus demonstrating that the lack of 
GR augments cutaneous inflammation during carcinogenesis, which may contribute to the 
development and progression of skin tumors.  
 
Altered keratinocyte differentiation and constitutively increased AKT and STAT3 
activities in GREKO skin papillomas 
 
Well-differentiated benign papillomas express normal markers of the epidermal basal (K5) and 
suprabasal (K10, loricrin) layers but not those of internal stratified epithelia such as K13 (Abel 
et al., 2009). Assessment of the expression of these keratins is routinely used to classify 
papillomas into low, intermediate or high risk of malignant conversion. The 
immunohistochemical analysis of CO skin tumors showed expression of K5 throughout all 
layers as well as suprabasal K10 and loricrin restricted to the most differentiated outer layers 
(Fig. 4a-c). We did not detect any CO papilloma with K13 expression (Fig. 4 d). In contrast, 
GREKO tumors showed a reduction in K10 positive layers and focal loss of loricrin 
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 (Fig. 4b´, c´, arrowheads) with 30% of the tumors staining positive for K13 (Fig. 4d´). 
Moreover, we detected reduced expression of the epithelial marker E-cadherin, which mediates 
cell-cell adhesion, in regions of GREKO but not in CO tumors (Fig. 4 e, e´). Immunobloting of 
protein extracts from papillomas for E-cadherin failed to show a statistically significant 
difference between genotypes, perhaps due to the focal nature of the decreased expression in 
GREKO tumors (not shown). Our data show that augmented proliferation and inflammation, as 
well as defective differentiation of epidermal keratinocytes lacking GR contributed to the 
accelerated onset and development of skin tumors of GREKO mice. Overall, these features 
indicate that the lack of epidermal GR triggers early stages of	malignant conversion in GREKO 
mouse skin tumors. 
Previous reports have demonstrated that several signaling pathways including AKT, 
ERK and STAT3 play a critical role throughout the process of epithelial carcinogenesis in 
mouse skin (Segrelles et al., 2002, Kataokay et al., 2008). We have also shown that AKT and 
ERK activities were constitutively increased in the epidermis of mice with either total or 
keratinocyte-specific inactivation of GR (Bayo et al., 2008; Sevilla et al., 2013). Moreover, 
growth kinetics and malignancy of skin tumors induced by the injection of AKT-transfected 
mouse keratinocytes was greatly reduced by GR co-expression due to a non-genomic interaction 
of GR and p85/PI3K (Leis et al., 2004). Accordingly, we examined whether the increased 
sensitivity of GREKO mice to develop epidermal tumors correlated with increased activity of 
these signaling pathways. Phosphorylated (p)-ERK is normally restricted to the granular layer of 
the epidermis (Fig. 4f, white arrows); however, increased levels of p-ERK were detected in all 
epidermal layers in GREKO tumors (Fig. 4f´, white and black arrows). p-AKT was detected in 
tumors from both genotypes although the levels and the number of positive cells were increased 
in GREKO relative to CO mice (Fig. 4g, g´). STAT3 was localized in some nuclei of CO 
epidermal tumors (Fig. 4h) whereas virtually all nuclei of GREKO tumors were STAT3-positive 
(Fig. 4h´), consistent with the critical role of this transcription factor in multistage epithelial 
carcinogenesis (Kataokay et al., 2008). Quantitation of immunoblotting experiments showed 
that the ratios of both p-AKT/AKT and p-STAT3/STAT3 but not p-ERK/ERK were increased 
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with statistical significance in GREKO relative to CO papillomas (Fig. 4i, j). The inability to 
observe changes in p-ERK levels may be due to dilution effects as stromal cells are also present 
in the protein extracts. These results suggest that the lack of epidermal GR not only accelerates 
the growth of epidermal tumors but also increases their malignancy likely due, at least in part, to 
the increased activation of AKT and STAT3 pathways. 
 
GR-deficiency alters cytoskeletal architecture and triggers a partial epithelial-
mesenchymal transition in cultured keratinocytes 
 
Given that GREKO mouse skin tumors featured signs of malignant conversion (Figs. 1 
and 4), we further analyzed the morphology and cell-cell interactions of GREKO vs CO cultured 
keratinocyte cell lines (Sevilla et al., 2013). At confluency, GREKO keratinocytes featured 
dramatic morphological alterations, showing spindle-like phenotype suggestive of a partial 
epithelial-mesenchymal transition (EMT, Moreno-Bueno et al., 2009; Fig. 5a, a´). This was 
confirmed by immunofluorescence staining for E-cadherin and smooth muscle actin (SMA), as 
epithelial and mesenchymal expression markers, respectively. Whereas confluent CO 
keratinocytes exposed to 1.2 mm calcium showed E-cadherin mediated cell-cell contacts, GREKO 
keratinocytes showed decreased cell-cell contacts with almost undetectable E-cadherin 
expression levels (Fig. 5b, b´). Consistent with the absence of E-cadherin, GREKO keratinocytes 
did not form mature intercellular junctions shown by the reduced accumulation of -catenin and 
desmoplakin at sites of cell-cell contact (Fig. 5c, c´, d, d´). Importantly, the expression of SMA 
was greatly increased in GREKO keratinocytes although these cells still retained K5 expression 
(Fig. 5e, e´). These results were further confirmed by immunoblotting (Fig. 5g, h). Down-
regulation of E-cadherin is mediated by members of the Snail family of proteins through binding 
to an E-box located in its promoter (Moreno-Bueno et al., 2009). Indeed, we detected a 
statistically significant increase in Snail but not Slug/Snai2 levels in GREKO relative to CO 
keratinocytes (Fig. 5g, h). These data are consistent with the observation that Dex-activated GR 
abolished Snail binding to the E-cadherin promoter in lung epithelial cells, thus contributing to 
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EMT supression (Zhang et al. 2010). The observed changes in GREKO cultured keratinocytes 
were independent of media composition (Fig. S5). 
We evaluated the actin cytoskeleton by phalloidin staining and observed a reduction in 
cortical actin and an increase in stress fibers in GREKO vs CO cells  (Fig. 5f, f´), another hallmark 
of EMT (Moreno-Bueno et al. 2009). Since cytoskeleton reorganization could be linked to 
altered cell motility, we evaluated migration of GREKO vs CO keratinocytes in a scratch wound 
assay but did not detect statistically significant changes in wound closure (not shown). This 
might be related to the lack of Slug up-regulation in GREKO keratinocytes, which is essential for 
re-epithelialization of healing wounds and cannot be substituted by Snail (Sou et al., 2010). 
Our in vitro results were consistent with the in vivo findings showing that the lack of 
epidermal GR increases the malignancy of epidermal tumors (Figs. 1, 4 and 5). However, 
immunoblotting of protein extracts from tumors of both genotypes did not show statistically 
significant changes in E-cadherin or SMA (not shown), likely due to the fact that in vivo EMT is 
restricted to a subset of tumor cells.  There are contradictory reports regarding the role of GR in 
EMT, and cell-type specificity seems to be key for the final outcome of GC treatments. Recent 
studies have shown negative regulation of GCs on the process of EMT, which is vital for tumor 
invasion and metastasis (Godoy et al. 2009, Zhang et al. 2010; Ferrand 2012).  
Given the immunosuppressive effects of GCs, there has been concern that their chronic 
use was associated with an increased risk of several cancers, including non-melanoma and 
melanoma skin cancer. The epidemiological data are controversial claiming either no 
association between the use of GCs and cancer risk or a modestly increased risk of basal or 
squamous cell carcinoma (Karagas et al, 2001; Sorensen et al, 2004; Askling et al, 2005; 
Baecklund et al, 2006; Jensen et al., 2009). However, it is feasible that the reported increase of 
cancer risk is due to the inflammatory condition of the chronic diseases being treated and the 
use of other immunosuppressive agents rather than to the contribution of GCs per se. The use of 
a mouse model with epidermal GR-ablation demonstrates that GR negatively regulates the 
formation and early malignization of DMBA/PMA-induced epidermal tumors as well as the 
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development of sebaceous tumors and MF. Our findings highlight the complexity of GR action 
in tumorigenesis as well as the relevance of epidermal GR for cross-talk with other skin cells. 
 
MATERIALS AND METHODS 
Animal experimentation and skin carcinogenesis protocols 
GREKO mice and genotyping of the transgenic colonies has been previously reported (Sevilla et 
al., 2013). Briefly, K5-cre+/-//GRloxP/loxP male mice were crossed with 0-cre//GRloxP/loxP females 
and the resulting adult progeny (K5-cre+/-//GRloxP/loxP or GREKO and 0-cre//GRloxP/loxP or CO mice) 
were used for the indicated experiments (n= 56). The genetic background of the transgenic line 
was C57BL/6J//DBA/2J.  
Two protocols with different doses of DMBA/PMA were used where GREKO and CO 
mouse littermates were DMBA-initiated at the age of 8-wks. In the first protocol, a single dose 
of DMBA was applied (23 nmol) followed by repeated topical treatments with PMA 
(10g/mouse twice weekly for 19 wks) (n=38, 18 males (8 CO, 10 GREKO) and 20 females (10 
CO, 10 GREKO). In the second protocol, DMBA (390 nmol) was applied at a single dose 
followed by repeated topical PMA treatments (6g/mouse three times weekly for 31 wks) 
(n=18; 7 males (3 CO, 4 GREKO) and 11 females (5 CO, 6 GREKO). The appearance of tumors 
and abnormally pigmented skin (located on dorsal and lateral skin) was recorded weekly. 
Tumors and adjacent skin were collected at experimental endpoints and either fixed in 4% 
paraformaldehyde or 70% ethanol or snap frozen in liquid nitrogen for future isolation of RNA 
and protein. A variable number of tumors and MF was collected from each genotype to perform 
histopathological analysis as well as RNA and protein isolation. For histopathological analysis, 
46 papillomas were evaluated (20 papillomas collected from 18 CO and 26 papillomas collected 
from 20 GREKO); 18 sebaceous adenomas (8 collected from 8 CO and 10 collected from 10 
GREKO); and 14 MF (6 collected from 6 CO and 8 collected from 8 GREKO). At least 10 
papillomas and 10 sebaceous adenomas were used for immunostaining. 
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Differences in the average number of papillomas per mouse during tumor promotion 
were assessed using the Student’s t-test, and statistical significance among genotypes indicated 
(p < 0.05). The major axis of tumors was measured at the experimental endpoint and the mean 
number of papillomas per mouse greater or less than 2mm was calculated; statistical 
significance of differences between genotypes was determined using the Student’s t-test 
(p<0.05).  
Mice were housed in standard temperature and humidity conditions and experimentation 
was conducted with accepted standards of humane care in our animal facility (Instituto de 
Biomedicina de Valencia IBV-CSIC). Experiments were performed in accordance with the 
current Spanish and European normative that governs research with animals (Real Decreto 
1201/2005, B.O.E. #252, 10 of October, 2005 and Convenio Europeo 1-2-3 del 18/3/1986). 
 
RNA isolation and Quantitative RT-PCR 
Total RNA was isolated from skin adjacent to tumors of GREKO and CO mice (at least, five 
animals of each genotype) using Trizol (Invitrogen Life Technologies, Carlsbad, CA). cDNA 
was generated from 1 g of total RNA using RevertAid H Minus Reverse Transcriptase and 
oligo-dTs (Thermo Fisher Scientific, Waltham, MA) followed by quantitative PCR using 
specific oligonucleotides for each of the genes tested and FastStart Universal SYBR Green 
Master Rox (Roche Applied Science, Branford, CT) in an Applied Biosystems 7500 Fast real 
time PCR system (Life Technologies, Carlsbad, CA). Oligonucleotide sequences were: Il6F, 5´-
GATGCTACCAAACTGGATATAATC-3´; Il6R, 5´-GGTCCTTAGCCACTCCTTCTGTG-3´;. 
TnfaF, 5´-CCCTCACACTCAGATCATCTTCT-3´; TnfaR, 5´-
GCTACGACGTGGGCTACAG-3´; Il1bF, 5´-GCAACTGTTCCTGAACTCAACT-3´; Il1bR, 
5´-ATCTTTTGGGGTCCGTCAACT-3´. At least three biological replicates were used for each 
experimental group and technical triplicates were assessed to calculate the mean value ± SD. 
Statistical significance was calculated using the Student’s t-test, p < 0.05.  
 
Antibodies 
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The following rabbit polyclonal antibodies were used specific for Actin (A2668, Sigma-Aldrich, 
St. Louis, MO), p-AKT (ser-473; #9271, Cell Signaling Technology, Beverly, MA),  -catenin 
(sc-7199, Santa Cruz Biotechnology, Santa Cruz, CA), Desmoplakin (Ab14418, Abcam, 
Cambridge, MA), ERK (sc154, Santa Cruz),  p-ERK (Thr202/Tyr204; #4376, Cell Signaling), 
IL6 (407670, Calbiochem, San Diego, CA), GR (sc-1004, Santa Cruz), K5 (PRB-160P, 
Covance, Babco, Berkeley CA), K10 (PRB-159P, Covance), K13 (Ab16112, Abcam), Loricrin 
(PRB-145P, Covance), MR (Ab64457, Abcam), Slug (#9585, Cell Signaling), STAT3 (#9132, 
Cell Signaling).  
The rabbit monoclonal antibody for p-STAT3 was from Cell Signaling (#9145) and goat 
anti-AKT was from Santa Cruz (sc1619). 
The following mouse monoclonal antibodies were used specific for CyclinD1 (sc-450, 
Santa Cruz), E-cadherin (610181, BD Biosciences, San Jose, CA), p-c-Jun (sc822, Santa Cruz), 
SMA (Ab18147, Abcam), Snail (#3895, Cell Signaling) and Tubulin (clone DM1A, Sigma-
Aldrich). 
 
 Histological and Immunohistochemical analysis 
Fixed tumor and skin samples were embedded in paraffin. Consecutive 4 m-thick sections 
were stained with H&E for histopathological analysis. Prior to immunostaining, paraffin 
sections were dewaxed and microwaved in 10 mM citrate solution, then blocked with 5% fetal 
bovine serum, and incubated with primary antibody overnight. Slides were washed three times 
with PBS, incubated with biotin-conjugated secondary antibodies for 1 h (Jackson 
ImmunoResearch, West Grove, PA) and visualized with the Avidin-Biotin-Complex (ABC) kit 
from DAKO (Vectastain Elite, Vector Laboratories, Inc, Burlingame, CA) using diamino-
benzidine as chromogenic substrate for peroxidase. Slides were mounted and analyzed by light 
microscopy (Leica DM RXA2, Leica Microsystems, Wetzlar, Germany). 
 
In vivo epidermal BrdU labeling 
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Epithelial cell proliferation was measured by i.p. injection of BrdU (130 g/g of body weight, 
Roche) 1 h before sacrifice. BrdU incorporation was detected by immunohistochemistry of 
paraffin-embedded sections using a mouse anti-BrdU monoclonal antibody (Roche). The 
number of BrdU-positive and total cells was determined per 200m of interfollicular 
epithelium in each section. Experiments were performed in at least six individuals of each 
genotype and statistical significance assessed using the Student’s t-test, (p < 0.05).  
 
Immunoblotting 
Whole cell extracts (30 g) were prepared as previously described (Sevilla et al., 2013), boiled 
in Laemmli buffer and separated on 8% sodium dodecyl sulfate-polyacrylamide gels (SDS-
PAGE), then transferred to nitrocellulose filters (Hybond ECL, GE Healthcare). The 
membranes were stained with Ponceau S (Sigma-Aldrich) to verify equal protein loading and 
transfer. Filters were blocked 1h with 5% nonfat dry milk in PBS-0.1% Tween 20 and 
incubated with the indicated antibodies overnight at 4º C. After washing with PBS-0.1% Tween 
20, membranes were incubated with a peroxidase-conjugated secondary antibody (GE 
Healthcare), washed, and analyzed using the enhanced chemiluminiscence method (GE 
Healthcare), with the ImageQuant 4000 Biomolecular Imager (GE Healthcare). Representative 
panels for each immunoblot are shown along with quantitation of at least three independent 
experiments. 
 
Cell culture and immunoflorescence 
GREKO and CO keratinocyte cell lines were generated from 8-wk-old mouse dorsal skin as 
previously described (Sevilla et al., 2013) and cultured in DMEM-Ham’s F12 (3:1) medium 
supplemented with 1.8 × 10−4 mol/L adenine, 0.35 mM calcium, 10% chelex-treated FCS, 5 
g/ml insulin, 10-10 M cholera toxin and 10 ng/ml EGF. 
 To visualize cytoskeletal rearrangements and intercellular junctions, cells grown on 
coverslips were incubated with 1.2 mM calcium for 4h prior to fixation with 4% PFA. 
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Following washing with PBS, permeabilization with 0.2% Triton X100, and blocking in 5% 
donkey serum and 0.5% bovine serum albumin, cells were incubated with primary antibody 
overnight at 4oC. Following washing, cells were incubated with Alexa Fluor conjugated (488 or 
555) secondary antibodies (Life Technologies) and, where indicated, with TRITC-phalloidin 
(Sigma-Aldrich) or DAPI (Life Technologies). Samples were mounted using Mowiol 
(Calbiochem) and analyzed using a	Leica DM 1000 microscope. 
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Figure legends  
 
Fig. 1. Increased sensitivity of GREKO mice to DMBA/PMA-induced skin tumorigenesis 
and altered histopathology of GREKO tumors 
(a) Papilloma development evaluated in GREKO (n=20) and CO littermates (n=18) after a single 
dose of DMBA (23 nmol) followed by 10 g PMA/mouse twice weekly for 19 wks at the 
indicated times of promotion. (b) Mean tumor number per mouse (< 2mm and > 2mm) 
determined at end point (18 males (8 CO, 10 GREKO) and 20 females (10 CO, 10 GREKO). 
Average tumor numbers per mouse and statistical significance were determined; *, p<0.05; **, 
p<0.01, n=56, Student’s t-test.  (c-e, c´-e´) Representative H&E staining of 19-wk papillomas 
collected from CO (c-e) and  GREKO (c´-e´) mice (n=46 papillomas, 20 CO and 26 GREKO). Bars: 
100 m. *, Keratin pearls; discontinuous lines: diffuse epidermal (Ep)-stromal (St) border; 
arrows, keratinocyte atypia (e´). (f, f´) Immunostaining demonstrates delocalized expression of 
laminin A (f´) and K5-positive keratinocytes (g) invading the dermis (arrowheads) in GREKO 
tumors. (c-g) 15 papillomas collected from 6 CO and 9 GREKO were analyzed. Bars: f, f´, 100 
m; g, 50 m.  
 
Fig. 2. Increased incidence of sebaceous adenomas and melanocytic foci in GREKO relative 
to CO mice after high dose DMBA initiation and /PMA promotion 
(a) Skin tumor and (c) melanocytic foci (MF) development evaluated in GREKO (n=10; 4 males 
and 6 females) and CO littermates (n=8; 3 males and 5 females) after a high dose of DMBA 
(390 nmol) followed by 6 g PMA/mouse three times a week for 31 wks at the indicated times 
of promotion. Total numbers of sebaceous tumors and MF are represented. (b, b´) 
Representative H&E staining of 31-wk sebaceous adenomas (n=18, 8 CO and 10 GREKO) and 
(d, d´) MF (n=14, 6 CO and 8 GREKO) collected from each genotype.  Note the greater extent of 
the MF in GREKO relative to CO mice. Bar: 100 m. 
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Fig. 3. Increased keratinocyte proliferation and inflammation in GREKO skin papillomas 
(a, a´) GREKO papillomas showed increased BrdU-positive keratinocytes and (b, b´) augmented 
CycD1 expression; (c) negative control staining (slides incubated with secondary antibody 
alone). Bars: 100 m. Basal (black arrow) and suprabasal (white arrows) keratinocytes are 
indicated. (d) Percentage and statistical significance (*p<0.05, n=13, Student’s t-test) of BrdU-
positive basal keratinocytes. (e, e´) H&E staining of GREKO papillomas showing marked 
immune infiltrates within the epidermis (white arrows) and the tumor stroma (black arrows) of 
GREKO mice. (f, f´) Immunostaining for IL6. (g) Negative control. Bars: e, e´, 100 m; f, f´, g, 
50 m. (a-g) 13 papillomas collected from 5 CO and 8 GREKO were analyzed (h) Relative 
mRNA levels of Il6, Tnfa, and Il1b quantitated by RT-QPCR in GREKO and CO skin adjacent to 
tumors. Mean values ± SD are shown. (*p<0.05, n=7 skin samples collected from 3 CO and 4 
GREKO, Student’s t-test). 
 
Fig. 4. Altered keratinocyte differentiation and constitutively increased AKT and STAT3 
activities in GREKO skin papillomas 
(a-c, a´-c´) Immunostaining for K5, K10 and loricrin (LOR) shows abnormal differentiation of 
GREKO skin tumors relative to CO. Arrowheads, local negative staining for K10 and loricrin. (d-
e, d´-e´) Positive staining for K13 and focal reduced E-cadherin immunostaining of GREKO 
tumors indicates early malignization. (f-h; f´-h´) Immunostaining for phosphorylated (p)-ERK, 
p-AKT, and STAT3 shows constitutively increased activities/ nuclear localization in GREKO 
relative to CO epithelial tumors. White and black arrows denote suprabasal and basal staining, 
respectively. Bars: 100 m. (a-h) 11 papillomas collected from 4 CO and 7 GREKO were 
analyzed (i-j) Representative immunoblot and quantitation of three experiments shows relative 
expression and ratios of phosphorylated and total ERK, AKT, and STAT3 in GREKO and CO 
papillomas. Actin, loading control. Mean values ± SD are shown. (*p<0.05, n= 12 papillomas 
collected from 5 CO and 7 GREKO, Student’s t-test). 
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Fig. 5. Epidermal GR-deficiency triggers a partial epithelial-mesenchymal transition in 
cultured keratinocytes  
(a-f, a´-f´) Immunofluorescence staining for K5, E-cadherin, -catenin, desmoplakin, smooth 
muscle actin (SMA), and filamentous (F)-actin (phalloidin) in GREKO vs CO cells which were 
cultured in 0.35mm calcium (a, a´) or incubated for 4 h with 1.2 mm calcium (b-f, b´-f´) prior to 
fixation. In a and a´, keratinocytes were grown for an additional 48 h post confluency. Bars: 50 
m. g) Immunoblotting determined the relative expression of GR, E-cadherin, SMA, Snail, Slug 
and K5 in GREKO and CO cultured keratinocytes. Tubulin, loading control. (h) Quantitation of 
four independent experiments shows relative expression of the indicated proteins in GREKO 
compared to CO keratinocytes. Protein levels were arbitrarily set to 1 in CO cells. Mean values 
± SD are shown. (*p<0.05, **p<0.01, n=4, Student’s t-test). 
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Fig. S1. H-ras mutations and GR genotyping in control (CO) and GREKO tumors.
(a) Genomic DNA was isolated from paraffin sections of normal skin (NS), papillomas (Pap) and sebaceous adenomas (Seb) 
collected from CO and GREKO mice to identify H-ras mutations. Ethidium bromide stained gel shows representative examples of
undigested or XbaI-digested PCR products. Arrow: no mutation; asterisks: restriction susceptible allele containing the A-T mutation
in codon 61 of H-ras. (b) Nr3c1 (gr) status was determined by PCR in epidermis (E), Pap, Seb and melanocytic foci (MF) excised 
from CO and GREKO paraffin sections. The presence of the gr null allele demonstrates the inactivation of Nr3c1 gene in E, Pap, Seb
but not MF of GREKO mice. Note that MF are located in the dermis and thus, no recombination was detected. The detection of the 
band corresponding to the loxP/loxP allele in both Pap and Seb tumors is due to the presence of other cell types (stromal
component) in the tumors. As expected, Pap, Seb and MF of CO (0cre//GRloxP/loxP) mice only showed the gr loxP/loxP allele.
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Figure S2. Papilloma development in GREKO mice.
(a) Kinetics of tumor growth in GREKO (n=20; 10 males, 10 females) and control (CO) littermates (n=18; 8 males,
10 females) were evaluated after a single dose of DMBA (23 nmol) followed by 10 g PMA/mouse twice weekly
for 19 wks at the indicated times of promotion. Average tumor number per mouse and statistical significance per
gender was estimated (Student’s t-test; *, p<0.05; **, p<0.01; ***, p<0.005). (b) Percentage of mice with tumors
and total number of papillomas per genotype were determined at end point.
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Figure S3. Skin adjacent to control (CO) and GREKO tumors shows similar histology and
laminin A deposition. 
Skin adjacent to tumors was collected from CO and GREKO mice at 20-wks to evaluate histopathology (H&E)
as well as the expression of laminin A, which was restricted to the basement membrane in both genotypes.
Bars: 100 μm
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Figure S4. Expression of -catenin and p-c-Jun in control (CO) and GREKO sebaceous adenomas.
Immunostaining of CO and GREKO sebaceous adenomas collected at 31-wks showed similar expression of -
catenin and p-c-Jun. For -catenin, note the stronger staining in the epidermis relative to the tumors in both
genotypes. p-c-Jun staining is indicated by arrows. Bars: 100 m. 
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Figure S5. Medium composition does not alter epithelial-mesenchymal transition (EMT) phenotype of GREKO cultured
keratinocytes.
(a) Representative microphotographs of GREKO and control (CO) cells cultured in the presence or absence of cholera toxin (CT), 
EGF, or both. Bar 100 m. (b) relative expression levels of the indicated proteins isolated from (a) were determined by Western
blot. Tubulin (TUB), loading control. 
Latorre et al., Fig. S5
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SUPPLEMENTARY MATERIALS AND METHODS 
Ras mutation analysis 
Genomic DNA from normal skin, 12 papillomas, and 8 sebaceous adenomas of CO and GREKO 
mice was used for Ras mutation analysis. DNA was isolated from paraffin-embedded samples 
by using TaKaRa DEXPAT Easy kit (TaKaRa Bio Inc, Japan), and used as a template for PCR, 
as described (Park E, Zhu F, Liu B, Xia X, Shen J, Bustos T, Fischer SM, Hu Y (2007) 
Reduction in IκB kinase α expression promotes the development of skin papillomas and 
carcinomas. Cancer Research 67:9158-9168). Briefly, DNA was amplified by nested PCR for a 
region spanning codon 61 of the H-ras gene, before digestion with XbaI, which specifically 
recognizes the activating A-T mutation, and subjected to gel electrophoresis. A first 
amplification round using the primers: H-Ras A-F: 5’-
GGTGTAGGCTGGTTCTGTGGATTCTC-3’ and H-Ras A-R: 5’-
GCACACGGAACCTTCCTCAC-3’ resulted in a PCR product (329 bp) that was purified 
(QIAquick Gel Extraction Kit, Qiagen, Hamburg, Germany) and subjected to a second 
amplification round using the primers: H-Ras B-F: 5’-
TGTGGATTCTCTGGTCTGAGGAGAG-3’ and H-Ras B-R: 5’-
CATAGGTGGCTCACCTGTACTGATG-3’. The resulting 279 bp product was either left 
undigested or digested with Xba I restriction enzyme. Upon digestion, samples with no mutation 
gave only one band (279 bp) whereas samples with CAA to CTA mutation at codon 61 of the 
H-Ras gene resulted in the non-digested band plus two digestion products (145 bp and 124 bp). 
 
Nr3c1 (gr) genotyping 
Cell-type specific inactivation of Nr3c1 (gr) in epidermis, papillomas, sebaceous adenomas and 
MF was confirmed by PCR as previously described (Sevilla et al., 2013). 
 
Keratinocyte culture 
GREKO and CO keratinocytes were also cultured in the absence of cholera toxin and EGF to 
assess changes in cell morphology and the expression of EMT markers. 
